A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations
NCT07383506 · NOT YET RECRUITING · Phase 1
We track 1 ClinicalTrials.gov studies led by Cogent Biosciences Inc. The portfolio skews toward Phase 1 (1 trials).
1 clinical trials sponsored by Cogent Biosciences Inc.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 1 | 1 | 100% |
Cogent Biosciences Inc currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 1.
Cogent Biosciences Inc conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.